Dissolution and bracketing - EMA [Regulatives / Guidelines]

posted by ping4santosh  – India, 2020-03-20 12:38 (1767 d 19:50 ago) – Posting: # 21290
Views: 4,017

Hi Susanh,

We do face difficulties with the BCS IV drugs with low solubility.

If the reference product doesn't behave as the test product in Disso profile, you need to reformulate. What are your F values? Do you have separate F values with different strengths? If yes, pl share.

IMO, even if you follow the bracketing approach, you will have to prove the disso data for each strength you plan to register.

Could BE-studies been done on the highest and lowest strength and not on middle strengths in this case?

Yes, In Vivo BE studies can be done on the highest and lowest strengths.

Cheers, SKM

Complete thread:

UA Flag
Activity
 Admin contact
23,363 posts in 4,906 threads, 1,679 registered users;
111 visitors (0 registered, 111 guests [including 10 identified bots]).
Forum time: 08:29 CET (Europe/Vienna)

The combination of some data and an aching desire
for an answer does not ensure that a reasonable answer
can be extracted from a given body of data.    John W. Tukey

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5